Nordic Nanovector ASA
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was incorporated in 2009 and is headquartered in Oslo, Norway.
Nordic Nanovector ASA (8NN) - Total Assets
Latest total assets as of June 2025: €561.00 Million EUR
Based on the latest financial reports, Nordic Nanovector ASA (8NN) holds total assets worth €561.00 Million EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nordic Nanovector ASA - Total Assets Trend (2016–2024)
This chart illustrates how Nordic Nanovector ASA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Nordic Nanovector ASA - Asset Composition Analysis
Current Asset Composition (December 2024)
Nordic Nanovector ASA's total assets of €561.00 Million consist of 31.4% current assets and 68.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 29.6% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €245.82 Million | 59.3% |
| Goodwill | €37.22 Million | 9.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Nordic Nanovector ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nordic Nanovector ASA's current assets represent 31.4% of total assets in 2024, a decrease from 99.7% in 2016.
- Cash Position: Cash and equivalents constituted 29.6% of total assets in 2024, down from 97.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 67.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 59.3% of total assets.
Nordic Nanovector ASA Competitors by Total Assets
Key competitors of Nordic Nanovector ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Nordic Nanovector ASA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Nordic Nanovector ASA generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Nordic Nanovector ASA is currently not profitable relative to its asset base.
Nordic Nanovector ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.87 | 6.48 | 2.34 |
| Quick Ratio | 8.78 | 6.48 | 2.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €220.40 Million | € 28.50 Million | € 155.91 Million |
Nordic Nanovector ASA - Advanced Valuation Insights
This section examines the relationship between Nordic Nanovector ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.70 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 25.3% |
| Total Assets | €414.38 Million |
| Market Capitalization | $48.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values Nordic Nanovector ASA's assets below their book value (0.12 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Nordic Nanovector ASA's assets grew by 25.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Nordic Nanovector ASA (2016–2024)
The table below shows the annual total assets of Nordic Nanovector ASA from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €414.38 Million | +25.25% |
| 2023-12-31 | €330.83 Million | +201.73% |
| 2022-12-31 | €109.64 Million | -63.04% |
| 2021-12-31 | €296.67 Million | -5.70% |
| 2020-12-31 | €314.61 Million | -39.00% |
| 2019-12-31 | €515.72 Million | +8.90% |
| 2018-12-31 | €473.59 Million | -39.32% |
| 2017-12-31 | €780.47 Million | -25.30% |
| 2016-12-31 | €1.04 Billion | -- |